CORDIS
EU research results

CORDIS

English EN

Blood and bone – conjoined twins in health and disease: bone marrow analogs for hematological and musculoskeletal diseases

Objective

Blood and bone are closely intertwined. Their intrinsic regenerative capacities are disturbed in many hematological and musculoskeletal diseases. Re-establishing the regenerative potential is the key to cure these diseases by regenerative medicine. Multipotent stem cells of both tissues – hematopoietic stem cells (HSCs) for blood and mesenchymal stem/stromal (MSCs) for bone – are the basis for their regenerative capacity. While it is well established that HSCs are influenced by the bone marrow in their natural environment including MSCs and their progeny, surprisingly little attention has been paid to the reciprocal relationship. The hypothesis of the current proposal is that only when taking both tissues and their mutual crosstalk into account, we will be able to understand how the regenerative potential of blood and bone is impaired in disease and how it can be re-established with novel treatment strategies. For this purpose we need to understand the early events of disease onset and progression. Due to the limitations of such studies in human beings and animals, I propose to develop human in vitro models of healthy bone marrow, which can be induced to develop hematological and musculoskeletal diseases with high incidence, namely leukemia, multiple myeloma and bone metastasis. Previously my team and I developed a simplified bone marrow analog that bases on macroporous, cell-laden biomaterials with tunable physical, biochemical and biological properties. This versatility will enable us to create biomimetic human in vitro models of the human bone marrow in health and disease, which are ground-breaking in their applicability to investigate how the regenerative balance of bone marrow is maintained in health and disturbed in the different kinds of diseases – a prerequisite to develop novel regenerative treatments – as well as their scalability and thus suitability as in vitro test systems for screening of novel drugs or treatments.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER

Address

Welfengarten 1
30167 Hannover

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 355 804,54

Beneficiaries (2)

Sort alphabetically

Sort by EU Contribution

Expand all

GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER

Germany

EU Contribution

€ 1 355 804,54

KARLSRUHER INSTITUT FUER TECHNOLOGIE

Germany

EU Contribution

€ 144 115,46

Project information

Grant agreement ID: 757490

Status

Ongoing project

  • Start date

    1 February 2018

  • End date

    31 January 2023

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 1 499 920

  • EU contribution

    € 1 499 920

Hosted by:

GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER

Germany